The Law Offices of Frank R. Cruz filed the complaint, asserting that Zoetis executives failed to disclose critical weaknesses in the company's product portfolio. According to the filing, the demand for Librela, a canine pain medication, plummeted as veterinarians grew increasingly wary of FDA safety warnings concerning neurological complications.
Zoetis Investors Face July Deadline in Securities Fraud Class Action
Investors who incurred financial losses holding Zoetis Inc. stock between January 2025 and May 2026 have until July 27, 2026, to seek lead plaintiff status in a pending securities fraud lawsuit. The class action centers on allegations that the pharmaceutical company misled shareholders regarding the competitive standing of its veterinary products.
Beyond these safety concerns, the lawsuit claims Zoetis suffered from significant market erosion across its core lines. The company allegedly lost ground with Simparica Trio against lower-priced competitors, while its flagship dermatology treatments, Apoquel and Cytopoint, faced stiff competition from newly launched alternatives. Investors seeking to participate in the litigation or review their legal options can contact the firm via their Los Angeles office or through the provided contact channels.
Comments (0)
No comments yet. Be the first!